Galderma Group AG (SWX:GALD)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 35.73B +38.6% |
| Revenue (ttm) | 3.73B +8.6% |
| Net Income | 300.62M |
| EPS | 1.26 |
| Shares Out | 237.41M |
| PE Ratio | 119.05 |
| Forward PE | 47.26 |
| Dividend | 0.15 (0.10%) |
| Ex-Dividend Date | n/a |
| Volume | 335,389 |
| Average Volume | 372,520 |
| Open | 151.50 |
| Previous Close | 149.70 |
| Day's Range | 149.90 - 154.00 |
| 52-Week Range | 72.70 - 170.10 |
| Beta | n/a |
| RSI | 47.87 |
| Earnings Date | Mar 5, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ... [Read more]
Full Company ProfileNews
Galderma Group AG (GALDY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
TOXINS 2026: Clinical Updates on Galderma's Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
Galderma will present data on Relfydess ® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and ...
Galderma announces the authorization of NEMLUVIO® (nemolizumab) for atopic dermatitis and prurigo nodularis in Canada
NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. 1 IL-31 is a neuroimmune cytokine that drives itch and is involv...
New Published Data Confirms Galderma's Nemluvio Improves Itch And Sleep In 48 Hours
(RTTNews) - Galderma Group AG (GDERF, GALD.SW), a dermatology company, on Tuesday released new clinical findings confirming that Nemluvio showed significant relief of itch and sleep disturbances withi...
Galderma Group AG (GALDY) Q3 2025 Sales Call Transcript
Galderma Group AG (OTCPK:GALDY) Q3 2025 Sales Call October 23, 2025 9:30 AM EDTCompany ParticipantsEmil Ivanov - Head of Strategy, Investor Relations &...
Galderma Group AG (GALDY) Q3 2025 Sales/ Trading Statement Call - Slideshow
2025-10-23. The following slide deck was published by Galderma Group AG in conjunction with this event.
Galderma Announces Departure of Its Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland — Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, wi...
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
ZUG, Switzerland — Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild ...